Enveric Biosciences, Inc.
ENVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $49 | $79 | $329 |
| - Cash | $2 | $2 | $18 | $17 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $47 | $61 | $312 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | -$9 | -$17 | -$20 | -$56 |
| % Margin | – | – | – | – |
| Net Income | -$10 | -$0 | -$19 | -$49 |
| % Margin | – | – | – | – |
| EPS Diluted | -228.48 | -97.08 | -156 | -1,244.28 |
| % Growth | -135.4% | 37.8% | 87.5% | – |
| Operating Cash Flow | -$8 | -$14 | -$17 | -$11 |
| Capital Expenditures | $0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$8 | -$14 | -$18 | -$12 |